{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChangePercent": 0.0, "regularMarketPrice": 1.03, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.33, "sharesOutstanding": 124986000, "bookValue": 0.496, "fiftyDayAverage": 0.8463, "fiftyDayAverageChange": 0.18369997, "fiftyDayAverageChangePercent": 0.21706246, "twoHundredDayAverage": 0.885455, "twoHundredDayAverageChange": 0.14454496, "twoHundredDayAverageChangePercent": 0.16324371, "marketCap": 136073296, "priceToBook": 2.076613, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "exchange": "STU", "shortName": "Mereo Biopharma Group Ltd. (ADR", "longName": "Mereo BioPharma Group plc", "messageBoardId": "finmb_307970474", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "firstTradeDateMilliseconds": 1556863200000, "priceHint": 4, "regularMarketChange": 0.0, "regularMarketTime": 1683889832, "regularMarketDayHigh": 1.04, "regularMarketDayRange": "1.03 - 1.04", "regularMarketDayLow": 1.03, "regularMarketVolume": 0, "regularMarketPreviousClose": 1.03, "bid": 1.01, "ask": 1.15, "fullExchangeName": "Stuttgart", "financialCurrency": "GBP", "regularMarketOpen": 1.03, "averageDailyVolume3Month": 1693, "averageDailyVolume10Day": 5981, "fiftyTwoWeekLowChange": 0.70199996, "fiftyTwoWeekLowChangePercent": 2.1402438, "fiftyTwoWeekRange": "0.328 - 1.84", "fiftyTwoWeekHighChange": -0.81000006, "fiftyTwoWeekHighChangePercent": -0.4402174, "fiftyTwoWeekLow": 0.328, "fiftyTwoWeekHigh": 1.84, "earningsTimestamp": 1680033660, "earningsTimestampStart": 1680033660, "earningsTimestampEnd": 1680033660, "trailingAnnualDividendRate": 0.0, "symbol": "MAH0.SG"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "One Cavendish Place", "address2": "4th Floor", "city": "London", "zip": "W1G 0QF", "country": "United Kingdom", "phone": "44 33 3023 7300", "website": "https://www.mereobiopharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 36, "companyOfficers": [{"maxAge": 1, "name": "Dr. Denise  Scots-Knight Ph.D.", "age": 63, "title": "Co-Founder, CEO & Exec. Director", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": {"raw": 878669, "fmt": "878.67k", "longFmt": "878,669"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Charles  Sermon", "age": 53, "title": "Co-Founder, Gen. Counsel & Company Sec.", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 0, "fmt": null, "longFmt": "0"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. John P. Richard M.B.A., MBA", "age": 65, "title": "Co-Founder & Chief Bus. Officer", "yearBorn": 1957, "fiscalYear": 2022, "totalPay": {"raw": 0, "fmt": null, "longFmt": "0"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Christine  Fox CPA", "age": 41, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2022, "totalPay": {"raw": 0, "fmt": null, "longFmt": "0"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. John A. Lewicki Ph.D.", "age": 70, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2022, "totalPay": {"raw": 0, "fmt": null, "longFmt": "0"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jackie  Parkin", "age": 64, "title": "Sr. VP & Therapeutic Head", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 0, "fmt": null, "longFmt": "0"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Alexandra  Hughes-Wilson", "age": 51, "title": "Chief of Patient Access & Commercial Planning", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 0, "fmt": null, "longFmt": "0"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Suba  Krishnan", "age": 57, "title": "Sr. VP of Clinical Devel.", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 0, "fmt": null, "longFmt": "0"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Arun  Mistry", "title": "Therapeutic Area Head of Setrusumab", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ann  Kapoun Ph.D.", "title": "Sr. VP of Translational R&D", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}